Skip to main content

Critical Care Reviews Newsletter

Newsletter 529  |  January 30th 2022

Register for the free weekly newsletter

Latest Trial to be Added to the Critical Care Reviews Meeting 2022 Programme


Welcome to the 529th Critical Care Reviews Newsletter, bringing you the best critical care research and open access articles from across the medical literature over the past seven days.

The highlight of this week's edition is the long awaited publication of the RECOVERY-RS randomised controlled trial, investigating non-invasive respiratory support in patients with COVID-19-related hypoxaemic respiratory failure. We were fortunate to host the trial result presentation as a livestream back in August and the paper has now been published in JAMA.  The other highlights include a systematic review and meta analysis comparing high-flow nasal oxygen with noninvasive ventilation in extubated patients, and observational studies on clinical outcomes among patients with 1-year survival following intensive care unit treatment for COVID-19 & corticosteroids as a risk factor for COVID-19-associated pulmonary aspergillosis in intensive care patients. There are also guidelines on levosimendan in intensive care and emergency medicine & COVID-19 in intensive care medicine; narrative reviews on ECPella & tracheobronchial injury; editorials on timing for initiating renal replacement therapy  & difficult airway management in the cardiac operating room; and commentaries on light sedation for mechanically ventilated patients & clinical trial design during and beyond the pandemic; as well as correspondence on lung transplantation for Covid-19–related respiratory failure in the United States & the evolution of blood product use in trauma resuscitation

If you only have time to read one review article this week, try this one on a guide to immunotherapy for COVID-19.

Critical Care Reviews Meeting 2022

The latest addition to the Critical Care Reviews Meeting 2022 is the FIRST-ABC trial, investigating the use of high flow nasal oxygen, in comparison with continuous positive airway pressure, for non-invasive respiratory support in critically ill children. This master protocol encompasses 2 randomised controlled trials. The first trial ("Step-Up") compares the use of HFNO with CPAP in acutely unwell children requiring non-invasive respiratory support. The second trial compares HFNO with CPAP in recently extubated children ("Step-Down"). Further information on this, and the other trials so far on the #CCR22 programme, can be found on the meeting webpage. Registration for #CCR22, on June 15th to 17th at Titanic Belfast, is open.

I hope you find this newsletter useful.

Until next week



Supported by

My Intensive Care Logo